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Quality Standards
AbstrAct
Introduction The purpose of the quality standards 
document is to provide healthcare professionals, 
commissioners, service providers and patients with a 
guide to standards of care that should be met for the 
investigation and management of pulmonary nodules 
in the UK, together with measurable markers of good 
practice.
Methods Development of British Thoracic Society (BTS) 
Quality Standards follows the BTS process of quality 
standard production based on the National Institute 
for Health and Care Excellence process manual for the 
development of quality standards.
results 7 quality statements have been developed, 
each describing a key marker of high-quality, cost-
effective care for the investigation and management of 
pulmonary nodules, and each statement is supported 
by quality measures that aim to improve the structure, 
process and outcomes of healthcare.
Discussion BTS Quality Standards for the investigation 
and management of pulmonary nodules form a key 
part of the range of supporting materials that the 
Society produces to assist in the dissemination and 
implementation of guideline  
recommendations.
IntroDuctIon
The British Thoracic Society (BTS) has been 
at the forefront of the production of guide-
lines for best clinical practice in respiratory 
medicine since the Society was established 
over 30 years ago. The Society’s guideline 
production process is accredited by National 
Institute for Health and Care Excellence 
(NICE) Accreditation (November 2011, 
renewed in 2017), and the Society’s Guideline 
Production Manual1 setting out the detailed 
methodology and policy for the production 
of guidelines is reviewed annually by the BTS 
Standards of Care Committee (SOCC). 
A statement on quality standards based on 
each BTS guideline is a key part of the range of 
supporting materials that the Society produces 
to assist in the dissemination and implementa-
tion of a guideline’s recommendations.
The purpose of the quality standards docu-
ment is to provide commissioners, health-
care professionals, planners and patients 
with a guide to standards of care that should 
be met for pulmonary nodule investigation 
and management in the UK, together with 
measurable markers of good practice.
BTS quality standards are intended for:
 ► healthcare professionals to allow deci-
sions to be made about care based on the 
latest evidence and best practice
 ► people with pulmonary nodules under-
going investigation and treatment to en-
able understanding of what services they 
should expect from their healthcare pro-
vider
 ► service providers to be able to quickly and 
easily examine the clinical performance 
of their organisation and assess the stand-
ards of care they provide
 ► commissioners so that they can be confi-
dent that the services they are purchasing 
are high quality and cost-effective.
NICE Quality Standards and the NICE 
Quality Standards Process Guide2 were used 
as a model for the development of BTS 
Quality Standards.
A quality standard is a set of specific, concise 
statements that:
 ► act as markers of high-quality, cost-effec-
tive patient care across a pathway or clin-
ical area, covering treatment or preven-
tion
 ► are derived from the best available evi-
dence.
The rationale for these quality standards is 
drawn from evidence and recommendations 
summarised in the BTS Guidelines for the 
Investigation and Management of Pulmonary 
Nodules.3
Each quality standard includes the 
following:
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 ► A quality statement, which describes a key marker of 
high-quality, cost-effective care for this condition.
 ► Quality measures, which aim to improve the struc-
ture, process and outcomes of healthcare.
The quality measures are not intended to be new sets of 
targets or mandatory indicators for performance manage-
ment that need to be collected. The quality measures are 
specified in the form of a numerator and a denominator, 
which define a proportion or ratio (numerator/denom-
inator). It is assumed that the numerator is a subset of 
the denominator population. The suggested numer-
ator and denominator are provided to allow healthcare 
professionals and service providers to examine their clin-
ical performance in relation to each quality standard. It 
is recognised that no national quality indicators will be 
available for this condition, and institutions will need to 
agree locally what information is required for the denom-
inator to be used in each case, and what the expected level 
of achievement should be, given local circumstances. A 
brief description about the quality standard in relation to 
each audience is given.
The main source references for these quality standards 
are:
 ► BTS Guidelines for the Investigation and Manage-
ment of Pulmonary Nodules, 2015.3
 ► NICE Clinical Guideline Lung Cancer: diagnosis and 
management, 2011.4
 
 
 
 
 
There is no specific order of priority associated with the 
list of quality standards.
MethoD of workIng
A Quality Standards Working Group was convened in 
February 2016 and met in May 2016. Membership is 
given in table 1.
Members of the Quality Standards Working Group 
submitted Declaration of Interest forms in line with the 
BTS Policy, and copies of forms are available on request 
from BTS head office.
The draft document was considered in detail by the 
BTS Standards of Care Committee initially in October 
2016 and the BTS Quality Improvement Committee in 
March 2017.
The document was made available on the BTS website 
for public consultation for the period from 13 March to 
10 April 2017.
Following further revision, the document was submitted 
for approval to the BTS Standards of Care Committee in 
October 2017.
The Quality Standards document will be reviewed 
in 5 years from the date of publication or following 
the publication of a revised Guideline whichever is 
sooner.
 
 
Table 1 Quality Standards Working Group members
Name To represent: Location
Professor David Baldwin Co-chair Respiratory medicine, Nottingham
Dr Matthew Callister Co-chair Respiratory medicine, Leeds
Dr Ian Woolhouse RCP London representative Respiratory medicine, Birmingham
Professor Fergus Gleeson RCR representative Radiology, Oxford
Dr Kevin Franks Clinical oncology, Leeds
Dr Paul Cane Pathology, London
Jeanette Draffan
National Lung Cancer Forum for Nurses 
representative
Macmillan Lung Cancer Nurse Specialist, North Tees & 
Hartlepool
Mr David Waller SCTS representative Surgery, London
Dr Richard Graham BNMS representative Radiology, Bath
Dr Ahsan Akram Respiratory medicine, Edinburgh
Dr Puneet Malhotra Respiratory medicine, St Helens and Knowsley
Dr Manil Subesinghe Radiology, London
Dr Philip Pearson
BTS Quality Improvement Committee 
representative Respiratory medicine, Northampton
BNMS, British Nuclear Medicine Society; BTS, British Thoracic Society; RCP, Royal College of Physicians; RCR, Royal College of 
Radiologists; SCTS, Society of Cardiothoracic Surgeons.
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LIst of quALIty stAteMents
1.  People with non-calcified pulmonary nodules confirmed on CT have their nodule(s) assessed for risk of malignancy.
2.  People with solid pulmonary nodules have their nodules assessed by semi-automated volumetry in preference to manual 
diameter measurements where possible and appropriate (eg,  for smaller nodules and for measuring doubling time, when 
growth not obvious).
3. Positron emission tomography (PET)-CT examinations undertaken for assessment of solid pulmonary nodules are reported 
using qualitative assessment with an ordinal scale to define fluorodeoxyglucose (FDG) uptake as absent, faint, moderate or 
intense, in relation to background lung tissue and mediastinal blood pool, to facilitate use of the Herder risk prediction model.
4. People with pulmonary nodules confirmed on CT are offered discharge, further surveillance, further work up or treatment 
according to BTS guidelines (see for specific recommendations).
5. People with pulmonary nodules considered for definitive treatment and suitable for surgical intervention are offered 
lobectomy with pathological confirmation of malignancy by frozen section, if not previously confirmed, or anatomical 
segmentectomy if unfit for lobectomy.
6. People with pulmonary nodules considered for definitive treatment but who decline or who are unsuitable for surgery are 
offered ablative non-surgical treatment where safe.
7. People with pulmonary nodules confirmed on CT are offered verbal and written information that allows them to make an 
informed choice about their management.
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Quality statement 1 People with non-calcified pulmonary nodules confirmed on CT have their nodule(s) assessed 
for risk of malignancy.
Rationale To ensure patients with non-calcified pulmonary nodules on CT have their nodule(s) assessed for risk 
of malignancy to guide appropriate use of interval imaging and recommendation for further workup.
Quality measure Structure:
 ► Evidence of local arrangements and written clinical protocols to ensure that people with non-
calcified pulmonary nodules confirmed on CT have their nodule(s) assessed for risk of malignancy.
Process:
 ► Proportion of people with non-calcified pulmonary nodules confirmed on CT who have their 
nodule(s) assessed for risk of malignancy.
 ► Numerator: the number of people with non-calcified pulmonary nodules confirmed on CT who 
have their nodule(s) assessed for risk of malignancy.
 ► Denominator: the number of people with non-calcified pulmonary nodules confirmed on CT.
Description of what 
the quality statement 
means for each 
audience
Service providers:
 ► Ensure there are systems in place for people with non-calcified pulmonary nodules confirmed on 
CT to have their nodule(s) assessed for risk of malignancy and managed according to the latest 
recommendations.
Healthcare professionals:
 ► Refer people with non-calcified pulmonary nodules confirmed on CT to services where 
their nodule(s) are assessed for risk of malignancy and are managed according to the latest 
recommendations.
Commissioners:
 ► Ensure they commission services for people with non-calcified pulmonary nodules confirmed on 
CT to have their nodule(s) assessed for risk of malignancy and be managed according to the latest 
recommendations.
People with non-calcified pulmonary nodules confirmed on CT:
 ► Have their nodule(s) assessed for risk of malignancy and are managed according to the latest 
recommendations.
Relevant existing 
indicators
Local multidisciplinary team (MDT) minutes/database/audit
National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry
Source references BTS Guidelines for the Investigation and Management of Pulmonary Nodules, 20153; NICE Lung 
Cancer: Diagnosis and Management Guideline, 20114
Other information  ► BTS Pulmonary Nodule Risk Prediction Calculator https://www. brit- thoracic. org. uk/ standards- of- 
care/ guidelines/ bts- guidelines- for- the- investigation- and- management- of- pulmonary- nodules/ bts- 
pulmonary- nodule- risk- prediction- calculator/ (to be read in conjunction with the relevant sections 
of the above guideline).
 ► NHS England Service Specification for Thoracic Surgical Services https://www. england. nhs. uk/ 
publication/ thoracic- surgery- adults/
 ► NHS England Commissioning Guidance for the Whole Lung Cancer Pathway: https://www.
brit-thoracic.org.uk/media/396232/Clinical-Advice-for-the-Provision-of-Lung-Cancer-Services-
Aug-2017.pdf 
https://www.brit-thoracic.org.uk/media/382380/National-Optimal-LUNG-Pathway-Aug-2017.pdf
 ► NLCFN Patient Information: https://www. nlcfn. org. uk/ patient- information
Quality statement 2 People with solid pulmonary nodules have their nodules assessed by semi-automated  
volumetry in preference to manual diameter measurements where possible and appropriate 
(eg, for smaller nodules and for measuring doubling time, when growth not obvious).
Rationale To ensure patients with solid pulmonary nodules on CT have their nodule(s) assessed by the most 
accurate method, where possible to guide appropriate use of interval imaging and recommendation 
for further workup.
Quality measure Structure:
 ► Evidence of local arrangements and written clinical protocols to ensure that people with solid 
pulmonary nodules have their nodules assessed by semi-automated  volumetry in preference 
to manual diameter measurements where possible and appropriate (smaller nodules and for 
measuring doubling time, when growth not obvious).
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Process:
 ► Proportion of people with solid pulmonary nodules who have their nodule(s) assessed by semi-
automated  volumetry in preference to manual diameter measurements where possible and 
appropriate (smaller nodules and for measuring doubling time, when growth not obvious).
 ► Numerator: the number of people with solid pulmonary nodules who have their nodules assessed 
by semi-automated  volumetry in preference to manual diameter measurements where possible 
and appropriate (smaller nodules and for measuring doubling time when growth not obvious).
 ► Denominator: the number of people with solid pulmonary nodules confirmed on CT where 
volumetry is preferable to manual measurements and is possible and appropriate.
Description of what 
the quality statement 
means for each 
audience
Service providers:
 ► Ensure there are systems in place that provide nodule assessment by semi-automated  volumetry.
Healthcare professionals:
 ► Refer people with solid pulmonary nodules confirmed on CT to services where they can have their 
nodules assessed by semi-automated  volumetry in preference to manual diameter measurements 
where possible and appropriate.
Commissioners:
 ► Ensure they commission services for people with solid pulmonary nodules confirmed on CT to 
have their nodule(s) assessed by semi-automated volumetry in preference to manual diameter 
measurements where possible and appropriate.
People with solid pulmonary nodules confirmed on CT
 ► Have their nodule(s) assessed by semi-automated  volumetry in preference to manual diameter 
measurements where possible and appropriate.
Relevant existing 
indicators
Local MDT minutes/database/audit
National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry.
Source references BTS Guidelines for the Investigation and Management of Pulmonary Nodules, 20153; NICE Lung 
Cancer: Diagnosis and Management Guideline, 20114
Note:
To ensure accuracy of comparative measurements, serial volumetry should be measured using the 
same CT settings, same software and release version.
Other information  ► BTS Pulmonary Nodule Risk Prediction Calculator https://www. brit- thoracic. org. uk/ standards- of- 
care/ guidelines/ bts- guidelines- for- the- investigation- and- management- of- pulmonary- nodules/ bts- 
pulmonary- nodule- risk- prediction- calculator/ (to be read in conjunction with the relevant sections 
of the above guideline).
 ► NHS England Service Specification for Thoracic Surgical Services https://www. england. nhs. uk/ 
publication/ thoracic- surgery- adults/
 ► NHS England Commissioning Guidance for the Whole Lung Cancer Pathway: https://www.
brit-thoracic.org.uk/media/396232/Clinical-Advice-for-the-Provision-of-Lung-Cancer-Services-
Aug-2017.pdf 
https://www.brit-thoracic.org.uk/media/382380/National-Optimal-LUNG-Pathway-Aug-2017.pdf
 ► NLCFN Patient Information: https://www. nlcfn. orwg. uk/ patient- information
Quality statement 3
 
 
 
Rationale
PET-CT examinations undertaken for assessment of solid pulmonary nodules are reported 
using qualitative assessment with an ordinal scale to define FDG uptake as absent, faint, 
moderate or intense, in relation to background lung tissue and mediastinal blood pool, to 
facilitate use of the Herder risk prediction model.
The Herder risk prediction model is the most accurate at predicting malignancy in solid pulmonary 
nodules and has been validated in a UK population. It uses clinical and radiological factors in 
conjunction with FDG uptake within the pulmonary nodule to determine the risk of malignancy. The 
incorporation of FDG uptake has a synergistic effect on the predictive accuracy of clinicoradiological 
prediction models but is dependent on the accurate classification of FDG uptake within solid 
pulmonary nodules using qualitative assessment with an ordinal scale. The standardisation of 
reporting of FDG uptake within solid pulmonary nodules on PET-CT facilitates reliable reproducibility 
of the Herder risk prediction model in clinical practice.
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Quality measure Structure:
 ► Evidence that PET-CT reports for characterisation of solid pulmonary nodules are reported using 
qualitative assessment with an ordinal scale to define FDG uptake with nodules.
Process: 
 ► Proportion of patients undergoing PET-CT for characterisation of solid pulmonary nodules with 
FDG uptake within nodules categorised using qualitative assessment with an ordinal scale.
 ► Numerator: number of patients undergoing PET-CTs performed for characterisation of solid 
pulmonary nodules with FDG uptake within the nodules categorised using qualitative assessment 
with an ordinal scale.
 ► Denominator: number of patients undergoing PET-CTs performed for characterisation of solid 
pulmonary nodules.
Description of what 
the quality statement 
means for each 
audience
Service providers:
 ► Ensure that patients have timely access to PET-CT for characterisation of solid pulmonary nodules.
Healthcare professionals who report PET-CT
 ► Ensure standardisation of reporting of FDG uptake within solid pulmonary nodules on PET-CT 
using qualitative assessment with an ordinal scale.
Commissioners:
 ► Commission PET-CT for the characterisation of solid pulmonary nodules.
People having PET-CT undertaken for assessment of solid pulmonary nodules
 ► Have their scans reported to facilitate the use of the Herder risk prediction model, one of the most 
accurate models in predicting malignancy in solid pulmonary nodules.
Relevant existing 
indicators
Local MDT minutes/database/audit
National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry
Source references BTS Guidelines for the Investigation and Management of Pulmonary Nodules, 20153; NICE Lung 
Cancer: Diagnosis and Management Guideline, 20114; RCP/RCR Evidence-based indications for the 
use of PET-CT in the United Kingdom, 20165
Other information  ► BTS Pulmonary Nodule Risk Prediction Calculator https://www. brit- thoracic. org. uk/ standards- of- 
care/ guidelines/ bts- guidelines- for- the- investigation- and- management- of- pulmonary- nodules/ bts- 
pulmonary- nodule- risk- prediction- calculator/ (to be read in conjunction with the relevant sections 
of the above guideline).
 ► NHS England Service Specification for Thoracic Surgical Services https://www. england. nhs. uk/ 
publication/ thoracic- surgery- adults/
 ► NHS England Commissioning Guidance for the Whole Lung Cancer Pathway: https://www.
brit-thoracic.org.uk/media/396232/Clinical-Advice-for-the-Provision-of-Lung-Cancer-Services-
Aug-2017.pdf 
https://www.brit-thoracic.org.uk/media/382380/National-Optimal-LUNG-Pathway-Aug-2017.pdf
 ► NLCFN Patient Information: https://www. nlcfn. org. uk/ patient- information
Definitions BTS qualitative ordinal scale for classification of solid pulmonary nodules with FDG PET-CT
Absent: uptake indiscernible from background lung tissue.
Faint: uptake less than or equal to mediastinal blood pool.
Moderate: uptake greater than mediastinal blood pool.
Intense: uptake markedly greater than mediastinal blood pool.
Quality statement 4
 
 
Rationale
People with pulmonary nodules confirmed on CT are offered discharge, further 
surveillance, further workup or treatment according to BTS Guidelines (see Box 1 for specific 
recommendations)
To ensure that patients are not followed up inappropriately where the risk of follow-up is likely 
to outweigh the benefit. To ensure that patients with larger nodules are managed according to 
assessment of risk of malignancy by further surveillance, further workup or treatment.
Quality measure Structure:
 ► Evidence that local arrangements are in place to apply BTS guidelines to patients with pulmonary 
nodules to ensure they are offered discharge, further surveillance, further workup or treatment 
appropriately.
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Process: 
 ► Proportion of patients with pulmonary nodules who are offered discharge, further surveillance, 
further work up or treatment according to BTS guidelines as a proportion of all nodules under 
follow-up.
 ► Numerator 1: number of patients discharged.
 ► Denominator: number of patients with pulmonary nodules who meet the criteria for discharge.
 ► Numerator 2: number of patients offered surveillance, further work up or treatment.
 ► Denominator 2: number of patients with pulmonary nodules who meet the criteria for surveillance, 
further work up or treatment.
Description of what 
the quality statement 
means for each 
audience
Service providers:
 ► Ensure patients are managed within a system in accordance with the latest and available evidence 
to allow safe discharge, further surveillance, further work up or treatment of patients with 
pulmonary nodules according to BTS guidelines.
Healthcare professionals:
 ► Ensure they have a structure where they can safely discharge, or offer further surveillance, workup 
or treatment to patients with pulmonary nodules according to BTS guidelines.
Commissioners:
 ► Ensure that adequate resource exists to allow for initial assessment of a nodule (including semi-
automated  volumetric analysis) to enable the calculation of risk of malignancy, offer further 
imaging surveillance with volumetric CT, further workup with PET-CT and other investigations or 
definitive treatment.
People with pulmonary nodules confirmed on CT
 ► Are offered discharge, further surveillance, further workup or treatment according to BTS 
guidelines.
Relevant existing 
indicators
Local MDT minutes/database/audit
National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry
Source references BTS Guidelines for the Investigation and Management of Pulmonary Nodules, 20153; NICE Lung 
Cancer: Diagnosis and Management Guideline, 20114; Walter, J E et al. Occurrence and lung cancer 
probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the 
randomised, controlled NELSON trial, 20166
Quality statement 5 People with pulmonary nodules considered for definitive treatment and suitable for surgical 
intervention are offered lobectomy with pathological confirmation of malignancy by frozen 
section, if not previously confirmed, or anatomical segmentectomy if unfit for lobectomy.
Rationale To maximise the surgical resection rate for early stage lung cancer and to allow geographical and 
temporal comparison of resection rates to instruct service development.
To ensure an appropriate surgical strategy for resection that minimises lobectomy for benign disease, 
ensures anatomical resection for all pulmonary nodules confirmed as lung cancer and that, where 
appropriate, a completion lobectomy occurs during the same anaesthetic.
Quality measure Structure: 
 ► Evidence of local arrangements and written clinical protocols that ensure people with pulmonary 
nodules considered for definitive treatment and suitable for surgical intervention are offered 
lobectomy with pathological confirmation of malignancy by frozen section, if not previously 
confirmed, or anatomical segmentectomy if unfit for lobectomy.
Process: 
 ► Overall proportion of patients who have pulmonary nodules with pathological confirmation of 
malignancy that undergo surgical resection. 
 ► Proportion of patients undergoing lobar or segmental resection of malignant pulmonary nodules 
as one definitive procedure. 
 ► Proportion of patients undergoing wedge or segmental resection of pulmonary nodules with 
eventual benign diagnosis. 
Numerator 1: 
 ► Number of patients who have pulmonary nodules with pathological confirmation of malignancy 
that undergo surgical resection.
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Denominator 1: 
 ► Total number of patients who have pulmonary nodules with pathological confirmation of 
malignancy.
Numerator 2: 
 ► Number of patients undergoing lobectomy with intraoperative frozen section analysis, or 
undergoing anatomic segmentectomy where not fit for lobectomy.
Denominator 2: 
 ► Number of patients undergoing resection of pulmonary nodules without a preoperative diagnosis 
who are subsequently confirmed malignant.
Numerator 3: 
 ► Number of patients undergoing resection of pulmonary nodules with an eventual benign diagnosis 
who undergo lobectomy.
Denominator 3: 
 ► Number of patients undergoing surgical resection of pulmonary nodules by lobectomy.
(This fraction should be equivalent to 10% or less)
Description of what 
the quality statement 
means for each 
audience 
Service providers: 
 ► Ensure services are provided that ensure people with pulmonary nodules considered for 
definitive treatment and suitable for surgical intervention are offered lobectomy with pathological 
confirmation of malignancy by frozen section, if not previously confirmed, or anatomical 
segmentectomy, if unfit for lobectomy.
Healthcare professionals
 ► Ensure surgical involvement in MDT discussion of pulmonary nodules, and ensure that surgical 
strategy is appropriate for the clinical situation.
Commissioners:
 ► Commission specialist thoracic surgical services that offer lobectomy with pathological 
confirmation of malignancy by frozen section, if not previously confirmed, or anatomical 
segmentectomy, if unfit for lobectomy. Services will be supported by an expert lung cancer MDT.
People with pulmonary nodules considered for definitive treatment and suitable for surgical 
intervention
 ► Should be treated at specialist centres with adequate provision for preoperative assessment, and 
intraoperative management for both diagnosis and resection.
Relevant existing 
indicators
Local MDT minutes/database/audit
National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry
Source references BTS Guidelines for the Investigation and Management of Pulmonary Nodules, 20153; NICE Lung 
Cancer: Diagnosis and Management Guideline, 20114; BTS Guidelines on the Radical Management 
of Patients with Lung Cancer, 20107
Other information  ► BTS Pulmonary Nodule Risk Prediction Calculator https://www. brit- thoracic. org. uk/ standards- of- 
care/ guidelines/ bts- guidelines- for- the- investigation- and- management- of- pulmonary- nodules/ bts- 
pulmonary- nodule- risk- prediction- calculator/ (to be read in conjunction with the relevant sections 
of the above guideline).
 ► NHS England Service Specification for Thoracic Surgical Services https://www. england. nhs. uk/ 
publication/ thoracic- surgery- adults/
 ► NHS England Commissioning Guidance for the Whole Lung Cancer Pathway: https://www.
brit-thoracic.org.uk/media/396232/Clinical-Advice-for-the-Provision-of-Lung-Cancer-Services-
Aug-2017.pdf 
https://www.brit-thoracic.org.uk/media/382380/National-Optimal-LUNG-Pathway-Aug-2017.pdf
 ► NLCFN Patient Information: https://www. nlcfn. org. uk/ patient- information
Quality statement 6 People with pulmonary nodules considered for definitive treatment but who decline or who are 
unsuitable for surgery are offered ablative* non-surgical treatment where safe.
Rationale People who are unfit or decline surgery still stand to gain a lot from having early-stage lung cancer 
treated with curative intent. Such patients should therefore be offered alternative treatment with 
curative intent. The outcome of treatment is similar whether in biopsy confirmed malignancy or where 
unconfirmed.
Structure:
 ► Evidence of local arrangements and written clinical protocols to ensure that people with pulmonary 
nodules considered for definitive treatment but who decline or who are unsuitable for surgery are 
offered ablative non-surgical treatment where safe.
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Quality measure Process: 
 ► Proportion of people with pulmonary nodules with a > 70%  likelihood of malignancy or 
pathological confirmation of lung cancer who decline or are unsuitable for surgery, who are offered 
ablative non-surgical treatment where safe.
Numerator:
 ► The number of people with pulmonary nodules with a >70% likelihood of malignancy or 
pathological confirmation of lung cancer who decline or are unsuitable for surgery and who are 
offered ablative non-surgical treatment where safe.
Denominator:
 ► The number of people with pulmonary nodules with a >70% likelihood of malignancy or 
pathological confirmation of lung cancer who decline or are unsuitable for surgery.
Description of what 
the quality statement 
means for each 
audience 
Service providers: 
 ► Ensure there are systems and services in place for people with pulmonary nodules who decline or 
who are unsuitable for surgery to be offered ablative non-surgical treatment where safe.
Healthcare professionals:
 ► Offer referral to people with pulmonary nodules who decline or who are unsuitable for surgery for 
ablative non-surgical treatment where safe.
Commissioners:
 ► Ensure they commission services for people with pulmonary nodules who decline or who are 
unsuitable for surgery so that they can be offered ablative non-surgical treatment where safe.
People with pulmonary nodules who decline or who are considered unsuitable for surgery
 ► Are offered ablative non-surgical treatment where safe.
Relevant existing 
indicators
Local MDT minutes/database/audit
National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry
Source references BTS Guidelines for the Investigation and Management of Pulmonary Nodules, 20153; NICE Lung 
Cancer: Diagnosis and Management Guideline, 20114; BTS Guidelines on the Radical Management of 
Patients with Lung Cancer, 20107
Other information *Ablative treatment refers to stereotactic ablative body radiotherapy, radiofrequency ablation or 
microwave ablation.
 ► BTS Pulmonary Nodule Risk Prediction Calculator https://www. brit- thoracic. org. uk/ standards- of- 
care/ guidelines/ bts- guidelines- for- the- investigation- and- management- of- pulmonary- nodules/ bts- 
pulmonary- nodule- risk- prediction- calculator/ (to be read in conjunction with the relevant sections 
of the above guideline).
 ► NHS England Service Specification for Thoracic Surgical Services https://www. england. nhs. uk/ 
publication/ thoracic- surgery- adults/
 ► NHS England Commissioning Guidance for the Whole Lung Cancer Pathway: https://www.
brit-thoracic.org.uk/media/396232/Clinical-Advice-for-the-Provision-of-Lung-Cancer-Services-
Aug-2017.pdf 
https://www.brit-thoracic.org.uk/media/382380/National-Optimal-LUNG-Pathway-Aug-2017.pdf
 ► NLCFN Patient Information: https://www. nlcfn. org. uk/ patient- information
Quality statement 7 People with pulmonary nodules confirmed on CT are offered verbal and written information 
that allows them to make an informed choice about their management.
Rationale People with pulmonary nodules confirmed on CT should be provided with verbal and written 
information that allows them to make an informed choice about their management.
Quality measure Structure: 
 ► Evidence of local arrangements and written clinical protocols to ensure that people with pulmonary 
nodules confirmed on CT are offered verbal and written information that allows them to make an 
informed choice about their management.
Process: 
 ► Proportion of people with pulmonary nodules confirmed on CT who are offered verbal and written 
information that allows them to make an informed choice about their management.
Numerator: 
 ► The number of people with pulmonary nodules confirmed on CT who are offered verbal and 
written information that allows them to make an informed choice about their management.
Denominator: 
 ► The number of people with pulmonary nodules confirmed on CT excluding nodules with obvious 
benign features.
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Description of what 
the quality statement 
means for each 
audience 
Service providers: 
 ► Ensure there are systems in place to ensure people with pulmonary nodules confirmed on CT are 
offered verbal and written information that allows them to make an informed choice about their 
management.
Healthcare professionals: 
 ► Offer people with pulmonary nodules confirmed on CT verbal and written information that allows 
them to make an informed choice about their management.
Commissioners: 
 ► Ensure they commission services where people with pulmonary nodules confirmed on CT are 
offered verbal and written information that allows them to make an informed choice about their 
management.
People with pulmonary nodules confirmed on CT
 ► Are offered verbal and written information that allows them to make an informed choice about their 
management. This provides patients (and their carers) with the opportunity to ask questions and 
make comments in connection with the proposed management and about their care in general. They 
should be able to appreciate the balance of benefits and risks concerning nodule management.
Relevant existing 
indicators
Local MDT minutes/database/audit
National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry
Source references BTS Guidelines for the Investigation and Management of Pulmonary Nodules, 20153; NICE Lung 
Cancer: Diagnosis and Management Guideline, 20114
Other information  ► BTS Pulmonary Nodule Risk Prediction Calculator https://www. brit- thoracic. org. uk/ standards- of- 
care/ guidelines/ bts- guidelines- for- the- investigation- and- management- of- pulmonary- nodules/ bts- 
pulmonary- nodule- risk- prediction- calculator/ (to be read in conjunction with the relevant sections 
of the above guideline).
 ► NHS England Service Specification for Thoracic Surgical Services https://www. england. nhs. uk/ 
publication/ thoracic- surgery- adults/
 ► NHS England Commissioning Guidance for the Whole Lung Cancer Pathway: https://www.
brit-thoracic.org.uk/media/396232/Clinical-Advice-for-the-Provision-of-Lung-Cancer-Services-
Aug-2017.pdf 
https://www.brit-thoracic.org.uk/media/382380/National-Optimal-LUNG-Pathway-Aug-2017.pdf
 ► NLCFN Patient Information: https://www. nlcfn. org. uk/ patient- information
box 1 Specific guideline recommendations in relation to quality statement 4.
solid Pulmonary nodules
Offer discharge if:
1. the largest nodule is <80 mm3 or 5 mm diameter, except where there is a history of previous malignancy or the nodule was not seen on a previous CT within 2 years.
2. there are obvious benign features (diffuse central laminated or popcorn pattern of calcification or macroscopic fat) or typical perifissural or sub-pleural nodules.
3. people with solid pulmonary nodules who are stable by semi-automated volumetry at one year, or at 2 years if by diameter measurement.
Offer imaging follow-up with low radiation dose CT (LDCT) and semi-automated volumetric analysis if:
4. nodule(s) are <300mm3 or 8mm diameter, or have a calculated risk of malignancy of <10% Offer PET-CT to further assess risk of malignancy
5. nodule(s) that are ≥300mm3 or ≥8mm diameter and have a >10% risk of malignancy. Offer biopsy (may also elect to have surveillance imaging or definitive 
treatment)
6. nodules that have a risk of malignancy of 10 to 70% after PET-CT.
7. Offer definitive treatment with or without prior biopsy
8. if nodule(s) have a risk of malignancy of >70% after PET-CT.
sub-solid pulmonary nodules (ssn)
9. offer interval thin section LDCT at 3 months to people with sub-solid pulmonary nodules ≥5 mm diameter and subsequently manage them according to risk of 
malignancy with follow-up of persistent SSN for 4 years
Source references BTS Guidelines for the Investigation and Management of Pulmonary Nodules, 20153; NICE Lung Cancer: Diagnosis and Management Guideline, 20114; 
Walter, J. E et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled 
NELSON trial, 2016.6
Other information BTS Pulmonary Nodule Risk Prediction Calculator https://www.brit-thoracic.org.uk/standards-of-care/guidelines/bts-guidelines-for-the-investigation-
and-management-of-pulmonary-nodules/bts-pulmonary-nodule-risk-prediction-calculator/ (to be read in conjunction with the relevant sections of the above Guideline).
NHS England Service Specification for Thoracic Surgical Services https://www.england.nhs.uk/publication/thoracic-surgery-adults/
NHS England Commissioning Guidance for The Whole Lung Cancer Pathway https://www.brit-thoracic.org.uk/media/396232/Clinical-Advice-for-the-Provision-of-Lung-
Cancer-Services-Aug-2017.pdf https://www.brit-thoracic.org.uk/media/382380/National-Optimal-LUNG-Pathway-Aug-2017.pdf
NLCFN Patient Information: https://www.nlcfn.org.uk/patient-information
Note: Integration of nodule volumetry software with other radiology systems used for image management and reporting is important to reduce reporting times and ensure 
images are stored appropriately for future reference.
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gLossAry of terMs
Definitive treatment: removal or ablation of the nodule 
with curative intent.
Ablative treatment: stereotactic ablative body radio-
therapy, radiofrequency ablation or microwave ablation.
bts quality standards for the investigation and management of  
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